Lonza
Lonza is a healthcare manufacturing organization helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. They help their customers to deliver new and innovative medicines that treat a wide range of diseases, allowing their patients to benefit from life-saving and life-enhancing treatments.
Latest Content
Online Event
Advances in Drug Discovery & Development 2024
On-Demand
This online event is aimed at those working within academia and pharmaceutical drug development, who want to hear from experts across their field. Focus will be given to the latest advances in small molecule drug discovery and development.
Article
Challenges and Solutions in Cell Therapy Development
In this article, we explore how researchers are tackling some of the challenges preventing cell therapies from being more widely used.
Product
Advertisement
Human Hepatocytes, Cryopreserved, Plateable and Interaction Qualified
Lonza's cryopreserved, plateable human hepatocytes, HUCPI, are characterized for transporter activity, enzyme activity, and enzyme gene induction potential.
Donor-matched NPCs are available. All liver-derived cells have an optimized media system for thawing, plating, and maintenance.
Donor-matched NPCs are available. All liver-derived cells have an optimized media system for thawing, plating, and maintenance.
Product
Advertisement
Human Peripheral Blood Mononuclear Cells (PBMCs)
Peripheral blood mononuclear cells (PBMCs), are increasingly being used in the drug development pipeline for biological therapeutics.
App Note / Case Study
Assessing the Functionality of PBMCs After Cryopreservation
As PBMCs continue to see an increase in use in the testing of new biological therapeutic compounds, ensuring purified cells retain functionality after cryopreservation is critical.
Product News
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Wolfgang Wienand, currently CEO of Swiss CDMO Siegfried Holding AG, will become Chief Executive Officer of Lonza in the summer of 2024. Albert M. Baehny will retire from Lonza following a transition period.
eBook
Drug Discovery: Current Approaches and Future Perspectives
Through a selection of articles, interviews and graphics, this eBook will provide readers with an overview of drug discovery, design and development, highlighting challenges and solutions, successes, various modalities and approaches.
Product News
Lonza and Oxford Nanopore To Collaborate on Novel Test To Accelerate Analysis of mRNA Products
Collaboration aims to commercialize a Current Good Manufacturing Practice (cGMP) validated test to enable advanced and innovative analysis for multiple critical quality attributes of mRNA products.
Product News
Jean-Marc Huët To Succeed Albert M. Baehny as Chairman of Lonza
Longstanding Chairman of Lonza, Albert Baehny will not stand for re-election. Jean-Marc Huët, currently Chairman of Heineken N.V. with strong international leadership track record to be proposed as the new Chairman of Lonza at the 2024 AGM.
Product News
Lonza Delivers Solid 2023 Performance With 10.9% Cer Sales Growth and 29.8% Core EBITDA Margin
Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%.
Advertisement
